Curia Global, Inc. (Curia), a contract research, development, and manufacturing organization, announced expansion plans to its Glasgow, UK facility and provided updates on the ongoing expansion in Albuquerque, NM.

Curia’s sterile fill-finish facility in Glasgow will add an integrated, isolator-based vial filling line and lyophilizer suitable for a broad range of drug products, more than doubling the current GMP batch size. 

Already known for its antibody-drug conjugates (ADCs), lipid nanoparticles (LNPs), lyophilization development, complex formulation and development, and clinical manufacturing experience, the Glasgow expansion will further strengthen Curia’s offering of sterile injectable product development.

New capabilities also include robotic, lossless filling technology situated within an isolator to allow filling speeds five times faster than current capabilities. The additional lyophilizer will also provide clinical-stage clients with more scalability. The facility will continue to serve clients during the expansion.  

Curia’s ongoing project at its Albuquerque facility includes two isolated filling lines that will add over 70,000 square feet to Albuquerque’s over 200,000-square-foot manufacturing space and will create significant phase III clinical and commercial capacity for its clients. 

A VarioSys Flex Line, suitable for small-scale biologics and non-potent small molecules can accommodate syringes, cartridges, and vials. This line is currently undergoing commissioning. 

Additionally, Curia’s new high-speed vial line will begin commissioning in Q3 2025. The new high-speed vial line includes two autoloaded freeze driers, automated vial inspection, and labeling/packaging for 2R to 30R vials.